Final antigenic Melan-A peptides produced directly by the proteasomes are preferentially selected for presentation by HLA-A*0201 in melanoma cells

Journal of Immunology

Volumn 173, Issue 10, 2004, Pages 6033-6040

  Chapatte, Laurence ^a   Servis, Catherine ^a,c   Valmori, Danila ^b   Burlet Schiltz, Odile ^c   Dayer, Johanna ^a   Monsarrat, Bernard ^c   Romero, Pedro ^b,d   Lévy, Frédéric ^a,d  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c INSTITUT DE PHARMACOLOGIE ET DE BIOLOGIE STRUCTURALE   (France)

^d National Center of Competence in Research in Molecular Oncology   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HLA A ANTIGEN; MELAN A; PROTEASOME;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MASS SPECTROMETRY; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; WESTERN BLOTTING;

EID: 8444252052     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.173.10.6033     Document Type: Article

References (30)

1. Rock, K. L., I. A. York, and A. L. Goldberg. 2004. Post-proteasomal antigen processing for major histocompatibility complex class I presentation. Nat. Immunol. 5:670.
2. Fruci, D., G. Lauvau, L. Saveanu, M. Amicosante, R. H. Butler, A. Polack, F. Ginhoux, F. Lemonnier, H. Firat, and P. M. van Endert. 2003. Quantifying recruitment of cytosolic peptides for HLA class I presentation: impact of TAP transport. J. Immunol. 170:2977.
3. Kunisawa, J., and N. Shastri. 2003. The group II chaperonin TRiC protects proteolytic intermediates from degradation in the MHC class I antigen processing pathway. Mol. Cell 12:565.
4. Cascio, P., C. Hilton, A. F. Kisselev, K. L. Rock, and A. L. Goldberg. 2001. 26S proteasomes and immunoproteasomes produce mainly N-extended versions of an antigenic peptide. EMBO J. 20:2357.
5. Paz, P., N. Brouwenstijn, R. Perry, and N. Shastri. 1999. Discrete proteolytic intermediates in the MHC class I antigen processing pathway and MHC I-dependent peptide trimming in the ER. Immunity 11:241.
6. Romero, P., D. Valmori, M. J. Pittet, A. Zippelius, D. Rimoldi, F. Lévy, V. Dutoit, M. Ayyoub, V. Rubio-Godoy, O. Michielin, et al. 2002. Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol. Rev. 188:81.
7. Rimoldi, D., K. Muehlethaler, S. Salvi, D. Valmori, P. Romero, J.-C. Cerortini, and F. Lévy. 2001. Subcellular localization of the melanoma-associated protein Melan-A/MART-1 influences the processing of its HLA-A2-restricted epitope. J. Biol. Chem. 276:43189.
8. Morel, S., F. Lévy, O. Burlet-Schiltz, F. Brasseur, M. Probst-Kepper, A.-L. Peitrequin, B. Monsarrat, R. Van Velthoven, J.-C. Cerottini, T. Boon, et al. 2000. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity 12:107.
9. Skipper, J. C. A., P. H. Gulden, R. C. Hendrickson, N. Harthun, J. A. Caldwell, J. Shabanowitz, V. H. Engelhard, D. F. Hunt, and C. L. Slingluff. 1999. Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100. Int. J. Cancer 82:669.
10. Valmori, D., J.-F. Fonteneau, C. M. Lizana, N. Gervois, D. Liénard, D. Rimoldi, V. Jongeneel, F. Jotereau, J.-C. Cerottini, and P. Romero. 1998. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J. Immunol. 160:1750.
11. Romero, P., N. Gervois, J. Schneider, P. Escobar, D. Valmori, C. Pannetier, A. Steinle, T. Wolfel, D. Liénard, V. Brichard, et al. 1997. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201- restricted Melan-A/ MART-1 antigenic peptide in melanoma. J. Immunol. 159:2366.
12. Valmori, D., F. Lévy, I. Miconnet, P. Zajac, G. C. Spagnoli, D. Rimoldi, D. Liénard, V. Cerundolo, J.-C. Cerottini, and P. Romero. 2000. Induction of potent anti tumor CTL responses by recombinant vaccinia encoding Melan-A peptide analogue. J. Immunol. 164:1125.
13. 2-terminal trimming of antigenic peptide precursors. Protein Expression Purif. 26:19.
14. Valmori, D., U. Gileadi, C. Servis, P. R. Dunbar, J.-C. Cerottini, P. Romero, V. Cerundolo, and F. Lévy. 1999. Modulation of proteasomal activity required for the generation of a CTL-defined peptide derived from the tumor antigen MAGE-3. J. Exp. Med. 189:895.
15. Lévy, F., L. Burri, S. Morel, A.-L. Peitrequin, N. Lévy, A. Bachi, U. Hellman, B. J. Van den Eynde, and C. Servis. 2002. The final N-terminal trimming of a subaminoterminal proline-containing HLA class I-restricted antigenic peptide in the cytosol is mediated by two peptidases. J. Immunol. 169:4161.
16. Vitiello, A., D. Marchesini, J. Furze, L. A. Sherman, and R. W. Chesnut. 1991. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J. Exp. Med. 173:1007.
17. Kawakami, Y., S. Eliyahu, K. Sakaguchi, P. F. Robbins, L. Rivoltini, J. R. Yanelli, E. Appella, and S. A. Rosenberg. 1994. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180:347.
18. Lucchiari-Hartz, M., P. M. van Endert, G. Lauvau, R. Maier, A. Meyerhans, D. Mann, K. Eichmann, and G. Niedermann. 2000. Cytotoxic T lymphocytes epitopes of HIV-1 Nef: generation of multiple definitive major histocompatibility complex class I ligands by proteasomes. J. Exp. Med. 191:239.
19. Dick, T. P., S. Stevanovic, W. Keilholz, T. Ruppert, U. Koszinowski, H. Schild, and H.-G. Rammensee. 1998. The making of the dominant MHC class I ligand SYFPEITHI. Eur. J. Immunol. 28:2478.
20. Lévy, F., N. Johnsson, T. Rümenapf, and A. Varshavsky. 1996. Using ubiquitin to follow the metabolic fate of a protein. Proc. Natl. Acad. Sci. USA 93:4907.
21. Kloetzel, P. M. 2004. Generation of major histocompatibility complex class I antigens: functional interplay between proteasomes and TPPII. Nat. Immunol. 5:661.
22. Reits, E., J. Neijssen, C. Herberts, W. Benckhuijsen, L. Janssen, J. W. Drijfhout, and J. Neefjes. 2004. A major role for TPPII in trimming proteasomal degradation products for MHC class I antigen presentation. Immunity 20:495.
23. Stoltze, L., M. Schirle, G. Schwarz, C. Schröter, M. W. Thompson, L. B. Hersh, H. Kalbacher, S. Stevanovic, H.-G. Rammensee, and H. Schild. 2000. Two new proteases in the MHC class I processing pathway. Nat. Immunol. 1:413.
24. Serwold, T., F. Gonzalez, J. Kim, R. Jacob, and N. Shastri. 2002. ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum. Nature 419:480.
25. Saric, T., S.-C. Chang, A. Hattori, I. A. York, S. Markant, K. L. Rock, M. Tsujimoto, and A. L. Goldberg. 2002. An IFN-γ-induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I-presented peptides. Nat. Immunol. 3:1169.
26. Dick, L. R., C. Aldrich, S. C. Jameson, C. R. Moomaw, B. C. Pramanik, C. K. Doyle, G. N. DeMartino, M. J. Bevan, J. M. Forman, and C. A. Slaughter. 1994. Proteolytic processing of ovalbumin and β-galactosidase by the proteasome to yield antigenic peptides. J. Immunol. 152:3884.
27. Mo, A. X. Y., S. F. L. van Lelyveld, A. Craiu, and K. L. Rock. 2000. Sequences that flank subdominant and cryptic epitopes influence the proteolytic generation of MHC class I-presented peptides. J. Immunol. 164:4003.
28. Gileadi, U., A. Gallimore, P. Van der Bruggen, and V. Cerundolo. 1999. Effect of epitope flanking residues on the presentation of N-terminal cytotoxic T lymphocyte epitopes. Eur. J. Immunol. 29:2213.
29. Del Val, M., H. J. Schlicht, T. Ruppert, M. J. Reddehase, and U. H. Koszinowski. 1991. Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein. Cell 66:1145.
30. York, I. A., A. X. Y. Mo, K. Lemerise, W. Zeng, Y. Shen, C. R. Abraham, T. Saric, A. L. Goldberg, and K. L. Rock. 2003. The cytosolic endopeptidase, thimet oligopeptidase, destroys antigenic peptides and limits the extent of MHC class I antigen presentation. Immunity 18:429.